(YOD) to Form Joint Venture with LA-Based Frequency Networks

New JV Frequency Asia will allow YOU On Demand to expand globally beyond China YOD Also Announces Strategic Investment for a 9% equity stake in Frequency Networks

NEW YORK, May 3, 2016  — YOU On Demand Holdings, Inc. (NASDAQ: YOD) (“YOU On Demand” or “YOD” or the “Company”), a premium content Video On Demand service provider in China evolving into a global, mobile-driven, consumer management platform for both enterprises and consumers, announced today that the Company and Frequency Networks, Inc. (“Frequency Networks”), a cloud-based internet video service that aggregates and distributes content from thousands of the world’s top providers, including the leading TV and Multi-Channel Networks, have entered into two agreements: 1. a binding agreement to form a Joint Venture called Frequency Asia (the “Frequency Asia JV”), dated April 13, 2016 (the “JV Agreement)” and 2. a Series A Preferred Stock Purchase Agreement  (the “Frequency SPA”) for the purchase by YOD of certain Frequency Series A Preferred Stock.

Frequency Networks, which has global partnerships with leading cable, satellite and mobile operators reaching over 150 million subscribers, builds and operates an intelligent content discovery platform that powers white-labeled video services and applications for TV and mobile devices.

The Frequency Asia JV

The Frequency Asia JV will have two main operational components that will provide YOU On Demand, via the JV, the opportunity to expand both its content offering and distribution footprint.

A.   Expanded Distribution: The JV will provide Frequency’s white-labeled platforms exclusively to the Asian region (including, but not limited to China, India, Philippines, Malaysia and Vietnam, etc.).  Utilizing a B2B distribution model, the JV will provide customized content services with multi-screen capability to large and established operators in the region.  Frequency Asia programming will include more than 70,000 channels, organized into 60+ unique vertical categories.  The viewing experience can be further optimized with personal feeds and channels driven by Frequency Networks’ enhanced metadata format and proprietary recommendation and video search engine.

B.   Global Content Channels: The JV will develop a stable of made-for-web channels with brand partners that integrates original and licensed content for categories including sports, fitness, music, food, tourism, science and more.  These channels will be rolled out globally across the JV’s distribution partners that include major cable, satellite and mobile operators in the US, Europe and Asia, and via direct-to-consumer apps for iOS, Android, Amazon Fire and other platforms.  The JV will also integrate and distribute third party e-commerce, social networking & affiliate marketing capabilities into its branded and white-labeled service.

In connection with the JV Agreement, Frequency Networks issued 6-year warrants to the Company exercisable at any time into up to 3,000,000 shares of Frequency Preferred Stock.

Series A Preferred Stock Purchase Agreement

In addition to the JV Agreement, the Company entered into the Frequency SPA for the purchase of $3 million of Series A Preferred Stock (the “Frequency SPA”).

The initial purchase of shares of Frequency Preferred Stock (at a purchase price of $2 million) was closed on April 13, 2016 (as described in YOU On Demand’s current report on Form 8-K, filed on April 19, 2016) and the remaining purchase of shares of Frequency Preferred Stock (at a purchase price of $1 million) closed on April 28, 2016.

YOU On Demand will have an approximate 9% ownership stake in Frequency Networks, Inc.  For a more detailed summary of the material provisions of the Frequency SPA and the JV Agreement, see YOU On Demand’s current report on Form 8-K, which has been filed with the U.S. Securities and Exchange Commission (“SEC”) at www.sec.gov.

Bruno Wu, Chairman of YOU On Demand, commented, “Today’s partnership announcement with Frequency is the first of what I hope to be many business development initiatives to come that should begin supporting the framework of our growth plan as well as the pledge to be more regularly and openly communicative.  With Frequency and YOD’s now multi-faceted partnership, YOU On Demand is reimagining, sharpening and expanding its fundamentals and original scope in three significant ways: 1. Moving from a pay only model to a pay, free and commerce content model which will be the cornerstone of establishing the world’s premier mobile-based multimedia, social networking & e-commerce-enabled network, 2. Broadening its geographical user base beyond China to become a true global brand and, 3. Moving from the existing user base of several million to an addressable user base of several hundred million users globally by the end of 2016.”

Frequency CEO Blair Harrison stated, “We’re thrilled to be partnering with YOU On Demand.  The creation of the Frequency Asia JV is a great opportunity to leverage YOD’s existing distribution and operations to accelerate the expansion of our platform and programming to cable, OTT and mobile operators in region.  YOD’s participation in our financing is a strong indicator of the value of Frequency’s platform and business model.”

About YOU On Demand Holdings, Inc. (http://corporate.yod.com)

YOU On Demand (NASDAQ: YOD) is a leading multi-platform entertainment service company delivering premium content, including leading Hollywood movie titles, to customers across China via Subscription Video On Demand and Transactional Video On Demand. The Company has secured alliances with leading global media operators and content developers.  YOU On Demand has content distribution agreements in place with many of Hollywood’s top studios including Disney Media Distribution, Paramount Pictures, NBC Universal and Twentieth Century Fox Television Distribution, Miramax, as well as a broad selection of the best content from Chinese filmmakers. The Company has a comprehensive end-to-end secure delivery system, governmental partnerships and approvals and offers additional value-added services. YOU On Demand has strategic partnerships with the largest media entities in China, a highly experienced management team with international background and expertise in Cable, Television, Film, Digital Media, Internet and Telecom. YOU On Demand is headquartered in both New York, NY and Beijing, China.

About Frequency (http://www.frequency.com)

Frequency is a cloud-based internet video service that aggregates and distributes video from thousands of the world’s top providers, including the leading TV and Multi-Channel Networks, and individual creators. TV, mobile and over-the-top operators use Frequency to deliver a complete internet video service to their subscribers. With one simple integration, operators have access to Frequency’s comprehensive portfolio of licensed content, and a fully featured video platform, including real time personalization. Frequency is now powering next-generation consumer video applications for operators on set-top boxes, mobile devices and the web. Frequency was founded by Blair Harrison in Los Angeles in 2010.  Harrison previously founded FastTV, an early internet video search site, and was CEO of online video entertainment site IFILM, sold to Viacom in 2005.

Safe Harbor Statement

This press release contains certain statements that may include “forward looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

CONTACT:
Jason Finkelstein
YOU On Demand
212-206-1216                                                          
jason.finkelstein@yod.com                                   
@youondemand
corporate.yod.com

(BSTG) to Host Pre-Clinical Research Update, Q1 Call

HOLLISTON, Mass., May 3, 2016  — Biostage, Inc. (NASDAQ: BSTG) a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, will host a conference call to provide an update on their collaborative large animal pre-clinical research and to review its first quarter results on Thursday, May 12, 2016 at 9:00am ET. The research update and Q1 2016 results will be announced pre-market that day.  On the call, management may respond to questions from the audience on any of a number of topics related to the business, including preclinical research, operations, plans and outlook.

Participating in the call will be CEO, Jim McGorry, Chief Medical Officer, Saverio La Francesca, and CFO, Tom McNaughton.

Conference Call Information:

Date/Time:  Thursday, May 12^th at 9:00 am ET

Call Dial In #:  877-407-8293 U.S. or 201-689-8349 Int’l

Live Webcast/Replay:  biostage.com/events-and-presentations

Audio Replay #:  877-660-6853 U.S. or 201-612-7415 Int’l – Access ID #13636819

About Biostage, Inc.: www.biostage.com
Biostage is a biotechnology company developing bioengineered organ implants based on the company’s new Cellframe^TM technology which combines a proprietary biocompatible scaffold with a patient’s own stem cells to create Cellspan^TM organ implants. Cellspan implants are being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the hope of dramatically improving the treatment paradigm for patients. Based on its preclinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.

Cellspan implants are currently being advanced and tested in a collaborative preclinical study. This testing is intended to expand the base of preclinical data in support of Biostage’s goal of filing an Investigational New Drug (IND) application with the U.S. FDA in late 2016. The IND will seek approval to initiate clinical trials for its esophageal implants in humans.

Forward Looking Statements:
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements in this press release include, but are not limited to, statements relating to the development expectations and regulatory approval of any of our products, including those utilizing our Cellframe technology, by the FDA, EMA, MHRA or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of our products, including those utilizing ourStonecold3 Cellframe technology,  which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, our ability to obtain and maintain regulatory approval for our products; plus other factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Biostage expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Twitter: BiostageIR

StockTwits:  BiostageIR

(ZG) Sellers Temper Expectations as Price Growth Slows in Brooklyn and Manhattan

NEW YORK, May 3, 2016  —

Key facts for Q1 2016:

• Manhattan’s median resale price rose 3.8 percent from last year to $978,765, the lowest annual growth since September 2012.
• The median resale price in Brooklyn grew 7.1 percent from last year to $545,330, the third consecutive month of slowing price growth.
• In Manhattan, sellers received 98.5 percent of their initial asking price, a slight increase from last year; Brooklyn sellers received 98.2 percent.
• The share of Manhattan listings with a price cut decreased from 31.2 percent in Q1 2015 to 27.6 percent in Q1 2016.
• In Brooklyn, the share of all sales inventory with a price cut declined to 22.7 percent, compared to 24.1 percent in the first quarter of 2015.

The Manhattan and Brooklyn sales markets continued to cool in the opening months of 2016. Manhattan’s median resale price grew 3.8 percent year-over-year to $978,765, the lowest annual increase since September 2012, according to the Q1 2016 StreetEasy® Market Reportsⁱ. In Brooklyn, the median resale price increased 7.1 percent from last year to $545,330, with monthly growth slowing since January 2016, as measured by the StreetEasy Price Indicesⁱⁱ.

In Manhattan, sellers may be exhibiting more disciplined pricing strategies to avoid price cuts, aligning their expectations with a market that is seeing slower price growth. The median sale-to-list price ratio in the borough was 98.5 percent in the first quarter, meaning sellers received almost all of their initial asking price, up from 97.7 percent last year. In an additional sign that sellers are exerting more price discipline, the share of all sales inventory that saw a price cut during the first quarter declined from 31.2 percent in 2015 to 27.6 percent. The typical price cut also declined from 6.9 percent in Q1 2015 to 6.7 percent in the first quarter of this year.

Brooklyn mirrored Manhattan, where sellers received 98.2 percent of their initial asking prices in the first quarter, unchanged from last year. Despite this stagnant number, the share of all sales inventory in Brooklyn with a price cut declined to 22.7 percent compared to 24.1 percent in the first quarter of 2015.

“Manhattan and Brooklyn sellers are being more cautious with their pricing and perhaps a little less free-wheeling than they’ve been over the past few years. In order to sell in this market, sellers need to lower their asking prices slightly to see a greater return with fewer price cuts,” said StreetEasy data scientist Alan Lightfeldt. “While price growth is slackening, buyers still face an extremely competitive and expensive market, especially in areas like East Brooklyn and Upper Manhattan where pockets of relatively affordable options are attracting more buyers every day.”

Since October 2014, Upper Manhattan has consistently shown the highest price growth in Manhattan, according to the StreetEasy Price Indices. The median resale price increased 9.7 percent from last year to $629,383 – more than twice as fast as Manhattan overall. Prices in the Upper West Side submarket rose 5.7 percent from last year, followed by Downtown (3.3 percent), Upper East Side (2.7 percent) and Midtown (1.7 percent).

In Brooklyn, price growth in the East Brooklyn submarket surged 23.9 percent from last year to $481,525 in March, the largest annual increase across both boroughs. The resale price in South Brooklyn increased 10.4 percent, followed by Prospect Park (6.1 percent), Northwest Brooklyn (3.4 percent) and North Brooklyn (2.4 percent).

According to StreetEasy Price Forecastsⁱⁱⁱ, all major submarkets will experience lower growth over the next 12 months, some even experiencing negative growth as we move past the cyclical peak of home shopping season. StreetEasy predicts that Brooklyn will continue to see overall price growth decline, most notably in parts of “Brownstone Brooklyn,” including the Northwest and Prospect Park submarkets. Price growth over the next 12 months across all of Brooklyn is expected to slow to 1.7 percent, considerably lower than the 7.1 percent annual growth of the first quarter. The median resale price in Manhattan is expected to grow by 2.6 percent over the next 12 months.

The complete StreetEasy Market Reports for Manhattan and Brooklyn with additional analysis, neighborhood data and graphics can be viewed at streeteasy.com/blog/market-reports.

About StreetEasy:
StreetEasy is New York City’s leading local real estate marketplace on mobile and the web, providing accurate and comprehensive for-sale and for-rent listings from hundreds of real estate brokerages throughout New York City and the major NYC metropolitan area. StreetEasy adds layers of proprietary data and useful search tools to help home shoppers and real estate professionals navigate the complex real estate markets within the five boroughs of New York City, as well as Northern New Jersey and the Hamptons.

Launched in 2006, StreetEasy is based in the Flatiron neighborhood of Manhattan. StreetEasy is owned and operated by Zillow Group (NASDAQ: Z and ZG).

StreetEasy is a registered trademark of Zillow, Inc.

ⁱ The StreetEasy Market Reports are a monthly overview of the Manhattan and Brooklyn sales and rental markets. Every three months, a quarterly analysis is published. The report data is aggregated from public recorded sales and listings data from real estate brokerages that provide comprehensive coverage of Manhattan and Brooklyn, with most metrics dating back to 1995 in Manhattan and 2005 in Brooklyn. The reports are compiled by the StreetEasy Research team. For more information, visit http://streeteasy.com/blog/market-reports/. StreetEasy tracks data for all five boroughs within New York City, but currently only produces reports for Manhattan and Brooklyn.
ⁱⁱ Median resale prices are measured by the StreetEasy Price Indices. Also referred to as the StreetEasy Manhattan Price Index (MPI) and StreetEasy Brooklyn Price Index (BPI), the metrics are monthly indices that track changes in resale prices of condo, co-op, and townhouse units. Each index uses a repeat-sales method of comparing the sales prices of the same properties since January 1995 in Manhattan and January 2005 in Brooklyn. Given this methodology, each index accurately captures the change in home prices by controlling for the varying composition of homes sold in a given month. Data on sales of homes is sourced from the New York City Department of Finance. Full methodology here: http://streeteasy.com/blog/methodology-streeteasy-price-indices/
ⁱⁱⁱ The Manhattan Price Forecast and the Brooklyn Price Forecast predict the change in resale prices 12 months out from the current reported period. Each forecast incorporates the Price Index for each borough as well as a mix of fundamental market factors including: historical recorded sales price, household income, population, and taxes.

(ECTE) Announces Significant Progress in Key Development Milestones

ISELIN, N.J., May 3, 2016  — Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced important advances in its next generation continuous glucose monitoring (CGM) system and its progress toward commercialization in China.

Echo has made significant progress in the development and initial internal clinical testing of key components of its next generation (NextGen) system. Important advancements were made in the NextGen sensor element, hydrogel and other key components of the Company’s highly disruptive technology to the episodic, needle-based glucose monitoring business. Improvements include a higher sensitivity to glucose with increased consistency, a shorter warm-up time, and resistance to acetaminophen interference. Additionally, the new streamlined design, that includes a flexible target base and transmitter housing, is more consumer-friendly and substantially less expensive than the prior version. A working prototype of the next generation CGM system is scheduled for June 2016.

In parallel to the progress made on the next generation system, Echo’s strategic partner Medical Technologies Innovation Asia (MTIA) is finalizing plans for the commencement of the upcoming China Food and Drug Administration (CFDA) clinical trial and the eventual regulatory approval and commercialization of Echo’s CGM in China. As previously announced, MTIA believes that Echo’s locally produced needle-free CGM will be designated as a Class 2 medical device with a review period of 90 working days after filing submission.  A formal and final designation from the CFDA is determined only at the time of submission. Approval of Echo’s CGM in China will signify the first non-invasive CGM to address the world’s largest diabetes population. In March, Echo’s team visited China where testing of the Company’s CGM showed linearity between locally manufactured sensors and U.S. produced sensors, marking the successful technology transfer. Echo’s final obligation related to the CFDA clinical trial is the software transfer, scheduled for mid-May, of the application program interface (API) and software application (App).  The API allows for the development of third party applications while increasing the security of Echo’s intellectual property.

“Echo has entered a new phase as we have developed and initiated testing of our NextGen system and approach the commencement of the CFDA regulatory trial. We have made tremendous strides toward our goal of delivering life-changing tools to people worldwide with diabetes,” said Scott W. Hollander, Echo’s President and CEO. “We remain on track to deliver our remaining milestones as scheduled and I look forward to providing a more detailed update in our conference call tomorrow.”

As previously announced, Echo will hold a conference call tomorrow, May 4, 2016, at 4:30 p.m. ET to provide an update on the Company’s progress and milestones. Participants can call (855) 327-6837 and reference Echo Therapeutics or pre-register for the call at http://bit.ly/1Wsz21D. The archived audiocast will be available for thirty (30) days following the call by visiting the Events section of Echo’s website at www.echotx.com.

About Echo Therapeutics

Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company’s CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the hospital settings. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo’s clinical studies, the safety and efficacy of Echo’s CGM System, the failure of future development and preliminary marketing efforts related to Echo’s CGM System, Echo’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo’s and its partners’ ability to develop, market and sell Echo’s CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its CGM System. These and other risks and uncertainties are identified and described in more detail in Echo’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2015, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(732) 201-4189   

Connect With Us:
– Visit our website at www.echotx.com
– Follow us on Twitter at www.twitter.com/echotx
– Join us on Facebook at www.facebook.com/echotx

(EXPI) Launches in 4 More States and the District of Columbia

Missouri, Kansas, Minnesota, Idaho and DC Newest Markets for Agent-Owned Brokerage

(ENOC) to Present at Needham Emerging Technology Conference

BOSTON, May 02, 2016  — EnerNOC, Inc. (Nasdaq:ENOC), a leading provider of energy intelligence software (EIS) and demand response solutions, today announced that Neil Moses, the Company’s Chief Operating Officer and Chief Financial Officer, is scheduled to participate at the Needham Emerging Technology Conference on Wednesday, May 18, 2016. The Company will webcast its presentation at approximately 5:00pm eastern daylight time (EDT). All interested parties can access the webcast live on the Company’s investor relations website at http://investor.enernoc.com.

About EnerNOC

EnerNOC is a leading provider of energy intelligence software (EIS) and demand response solutions. With capabilities to better address budgets and procurement, utility bill management, facility analysis and optimization, sustainability and reporting, project tracking, and demand management, EnerNOC’s enterprise SaaS platform helps businesses control energy costs, mitigate risk, and streamline compliance and sustainability reporting. EnerNOC also offers access to more demand response programs worldwide than any other provider, offering businesses a valuable payment stream to further enhance bottom line results. EnerNOC’s utility SaaS platform enables energy suppliers to forge deeper customer relationships, address regulatory mandates, and cost-effectively integrate demand-side resources to improve grid reliability through key capabilities, including customer engagement, demand response, energy efficiency, operational effectiveness, and wholesale procurement. For more information, visit www.enernoc.com.

Media Relations: 
Robin Woodcock
617.692.2601
news@enernoc.com 

Investor Relations:
Christopher Sands
617.692.2569
ir@enernoc.com

(CORI) Announces Streamlined Bioequivalence Development Path for Transdermal Corplex™

Reports Positive PK Results from Clinical Study of Optimized Once-weekly Corplex Donepezil for Alzheimer’s Disease

MENLO PARK, Calif., May 02, 2016  — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced receiving favorable written feedback from the U.S. Food and Drug Administration (FDA) on the company’s Pre-Investigational New Drug Application submission for once-weekly transdermal Corplex Donepezil.

Following review of Corium’s pre-IND submission, which included summary results from the initial Phase 1 pharmacokinetic (PK) study, the FDA provided clear guidance on the company’s development plans and registration pathway.  The agency advised Corium that if the company can adequately demonstrate bioequivalence between Corplex Donepezil Transdermal Delivery System (TDS) and oral Aricept^® (donepezil hydrochloride) in its planned PK bioequivalence studies, additional clinical efficacy studies will not be required.

“We are pleased that the FDA has concurred with our clinical development plan, which is intended to demonstrate bioequivalence between transdermal Corplex Donepezil and oral Aricept,” said Peter D. Staple, President and Chief Executive Officer of Corium.  “Preparations are underway for a pilot bioequivalence study, which we look forward to starting later this year.  Our objective is to use the results from this pilot study to finalize the design of a pivotal bioequivalence study that we expect to commence by mid-2017.”

If the results from the pivotal study supports bioequivalence, Corium expects to be able to submit a 505(b)(2) New Drug Application (NDA) as early as mid-2018.

Positive PK Results for Optimized Once-weekly Corplex Donepezil

Corium also announced positive findings from a new Phase 1 PK study evaluating optimized proprietary formulations of the once-weekly Corplex Donepezil product candidate.  Two formulations achieved comparable dosing to oral Aricept with PK profiles that demonstrate the potential for bioequivalence.  The company has selected a lead formulation based on these results.

Parminder “Bobby” Singh, Ph.D., Corium’s Chief Technology Officer and Vice President, R&D added, “Our optimized Corplex Donepezil patches achieved the targeted sustained delivery of donepezil and skin tolerability requirements for a once-weekly treatment, while also demonstrating enhanced reproducibility.  We look forward to advancing our lead formulation into a pilot bioequivalence study, followed by the pivotal bioequivalence study.”

Bioequivalence clinical studies are designed to assess the biological equivalence of pharmaceutical products based on their PK profiles, and are generally performed in healthy subjects.  These studies are relatively short in duration and provide a development path that is substantially less costly and more streamlined than typical clinical development programs, which require studies demonstrating safety and efficacy.

A Section 505(b)(2) NDA is a new drug application in which the applicant may rely on certain investigations of safety and effectiveness that were previously conducted by someone other than the applicant, and typically relates to an active drug substance that has previously been approved in a different form.

About Alzheimer’s Disease and Donepezil

Alzheimer’s disease is a progressive brain disorder in which the brain cells degenerate and die, causing a steady decline in memory and mental function.  An estimated 5.1 million Americans suffered from Alzheimer’s disease in 2015, with symptoms typically first appearing in people age 65 and older.  By 2025, the number of Americans age 65 and older with Alzheimer’s disease is estimated to reach 7.1 million.  Alzheimer’s disease is the most common cause of dementia among older adults.  Dementia ranges in severity from mild, when it is just beginning to affect a person’s functioning, to moderate, and severe, when the person must depend on others for the basic activities of day-to-day life.

Donepezil (the active ingredient in Aricept) is the most widely prescribed medication in a class of Alzheimer’s drugs known as cholinesterase inhibitors, and is approved for the treatment of mild, moderate and severe disease.  Donepezil is currently only available in tablet or orally disintegrating tablet form, each administered once daily, presenting compliance challenges for family members and caregivers who cannot rely on patients to consistently take their daily tablets, and is known to cause gastrointestinal side effects, including nausea, vomiting and loss of appetite.

About Corplex™

Corium’s Corplex system is a novel commercial-stage platform technology designed to broadly enable the transdermal delivery of small molecules, many of which have not previously been amenable to transdermal delivery.  Corplex advanced transdermal and transmucosal systems are broadly adaptable for use in multiple drug categories and indications, and have the potential to reduce quantities of active ingredient utilized in transdermal products.  Additionally, Corplex transdermal patches can enable efficient drug delivery, and adhere to either wet or dry surfaces for an extended period of time.  Corium’s Corplex technology has been successfully commercialized in Procter & Gamble’s Crest^® Whitestrips products, and is being utilized in several proprietary therapeutic products under development.

About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company’s broad experience with advanced transdermal and transmucosal delivery systems.  Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble.  The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor^®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins.  The company’s late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being developed with other partners.  Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis, and neurodegenerative and neurological disorders.  For further information, please visit www.coriumgroup.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our business strategy, clinical trial and regulatory timing and plans, the achievement of clinical and commercial milestones, and the advancement of our technologies and our products and product candidates.  Forward-looking statements are based on management’s current expectations and projections and are subject to risks and uncertainties, which may cause Corium’s actual results to differ materially from the statements contained herein.  Further information on potential risk factors that could affect Corium’s business and its results are detailed in Corium’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2015, filed with the Securities and Exchange Commission on February 12, 2016, and other reports as filed from time to time with the Securities and Exchange Commission.  Undue reliance should not be placed on forward-looking statements, especially guidance on future financial or operating performance, which speaks only as of the date they are made.  Corium undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

Corplex™ and MicroCor^® are registered trademarks of Corium International, Inc.
Aricept^® is a registered trademark of Eisai R&D Management Co., Ltd.
Crest^® Whitestrips is a registered trademark of The Procter & Gamble Company.

Investor and Media Contact:
BCC Partners
Karen L. Bergman 
kbergman@bccpartners.com
(650) 575-1509
Susan Pietropaolo
spietropaolo@bccpartners.com
(845) 638-6290

(FLML) Receives FDA Approval of Akovaz

(AST) Announces Oral Presentation at ASGCT 19th Annual Meeting

FREMONT, Calif., May 2, 2016  — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that clinical data from its AST-VAC1 (antigen-presenting autologous dendritic cells) immunotherapy clinical program will be presented during an oral session at the upcoming American Society of Gene and Cell Therapy (ASGCT) 19^th Annual Meeting, to be held on May 4-7, 2016 in Washington, D.C.

Jane S. Lebkowski, Ph.D., Asterias’ President of R&D and Chief Scientific Officer, will present the data, which is from the Company’s AST-VAC1 Phase 2 clinical trial in acute myelogenous leukemia (AML) and was first presented at the 2015 annual meeting of the American Society for Clinical Oncology (ASCO). The abstract is now available online on the ASGCT Annual Meeting website.

Presentation Details

Title: Long-Term Relapse-Free Survival of Patients with Acute Myeloid Leukemia (AML) Receiving a Telomerase-Engineered Dendritic Cell Immunotherapy
Abstract Number: 276
Session Title: Cancer-Immunotherapy, Cancer Vaccines I
Date: Thursday, May 5, 2016
Time: 5:00 – 5:15 PM
Room: Washington 4

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. is a leading biotechnology company in the emerging field of regenerative medicine. The company’s proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies.  Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology. AST-VAC1 (antigen-presenting autologous dendritic cells) demonstrated promise in a Phase 2 study in acute myelogenous leukemia (AML) and completed a successful end-of-Phase 2 meeting with the FDA in advance of initiating planning for a single pivotal Phase 3 AML study.  AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic immunotherapy. The company’s research partner, Cancer Research UK, plans to begin a Phase 1/2 clinical trial of AST-VAC2 in non-small cell lung cancer in 2017.  AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.

(ACRS) to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference

MALVERN, Pa., May 02, 2016  — Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that Dr. Neal Walker, President & Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10, 2016 at 1:40 p.m. PDT at the Encore at the Wynn Las Vegas, NV.

A live audio webcast of the Aclaris presentation can be accessed by visiting the “Investors” section of the company’s website at www.aclaristx.com. A replay of the webcast will be archived on the Aclaris Therapeutics website for 30 days following the presentation date.

About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology.  Aclaris Therapeutics, Inc. is based in Malvern, Pennsylvania and more information can be found by visiting the company’s website at www.aclaristx.com.

Contact:  

Aclaris Contact
Frank Ruffo
Chief Financial Officer
484-324-7933
investors@aclaristx.com

Investor Contact
Patricia L. Bank
Westwicke Partners
Managing Director
415-513-1284
patti.bank@westwicke.com

Media Contact
Mike Beyer
Sam Brown, Inc.
312-961-2502
mikebeyer@sambrown.com

(OPCO) Reports Record 2016 First Quarter Results

OurPet’s Company (OTCQX:OPCO) (www.ourpets.com), a leading proprietary pet supply company, today reports record net revenue and record net income for the three months ended March 31, 2016.

First Quarter 2016 net revenue increased 10.3% to $6.17 million compared to $5.59 million for the same period last year. Net income increased 24.7% to a record $266,581 for the 2016 first quarter compared to $213,792 a year ago. Earnings per diluted share were $0.01 for the first quarter of 2016 and 2015.

Dr. Steven Tsengas, Chairman and CEO comments, “These results reflect our continued ability to successfully execute our business strategy. Our E-Commerce and Food, Drug, Mass retail channels led the way this quarter with year over year sales growth of 14% and 8%, respectively. Q1’16 sales in the Pet Specialty market were about the same as Q1’15 sales, though we expect sales growth to improve for the balance of the year. International sales declined about 7.1% due to the strength of the US dollar. We are pleased that all major product categories showed a strong performance with Waste & Odor up 64%, Toys/Accessories up 10% and Bowls/Feeders up 9%.”

Dr. Tsengas continues, “Our profitability exceeded that of Q1’15 by almost 25%, though our gross profit margin of 29.7% was slightly below last year’s 30.3% due to product mix. S, G & A expenses as a percent of sales declined a full percent from 23.9% to 22.9%, a reflection of our maintaining tight cost controls. Income from operations increased 16.5% to $415,269 for the 2016 first quarter versus $356,313 for the 2015 first quarter mainly due to higher sales as S, G & A expenses increased by only $78,556. Our inventory also declined to approximately $7.44 million from approximately $7.91 million at the beginning of the year, the result of an ongoing initiative to reduce our inventory below $7,000,000 by year end without sacrificing any on-time or fill rate metrics.”

Dr. Tsengas concludes, “One of our highlights every first quarter is the Global Pet Expo international trade show held in Orlando, Florida where we present our new, innovative products to the market. This year we presented our new Intelligent Pet Care™ product line that features BlueTooth® and wireless connectivity for three products: our SmartScoop® – Intelligent Litter Box, our SmartLink™ Feeder – Intelligent Pet Bowl and our SmartLink™ Waterer – Intelligent Water Fountain. These products enhance the convenience of pet ownership and the connectivity between pets and pet owners by monitoring various activities that can be interpreted as indicators of pet health such as drinking, feeding and elimination behavior. This information is then transmitted to pet owners through their smartphones. We also introduced our 100% Natural Switchgrass BioChar litter, which produced favorable results when tested against the competition. Needless to say, we are really excited about the balance of 2016.”

About OurPet’s Company

OurPet’s Company designs, produces and markets a broad line of innovative, high-quality accessory and consumable pet products in the U.S. and overseas. Investor and customers may visit www.ourpets.com for more information about our company and its products. OurPet’s websites include www.petzonebrand.com and www.ourpets.com.

Certain of the matters set forth in this press release are forward-looking and involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially are the following: business conditions; growth in the industry; general economic conditions; addition or loss of significant customers; the loss of key personnel; product development; competition; risks of doing business abroad; foreign government regulations; fluctuations in foreign currency rates; rising costs for raw materials and sources of supply that may be limited or unavailable from time to time; the timing of orders booked; and the other risks that are described from time to time in OurPet’s SEC reports.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160502005119/en/

OurPet’s Company
Dr. Steven Tsengas, CEO, 440-354-6500, x111 (Direct)
Fairport Harbor, Ohio
or
Corporate Communications
DreamTeamNetwork (DTN)
Austin, Texas
512-758-8877 (Direct)
www.DreamTeamNetwork.com
Editor@DreamTeamNetwork.com

(GOLD) Randgold Resources: Vesting of CEO Career Shares Award

(MKTO) Raises $525 Million Across Two New Funds

$400 Million Mayfield XV Continues Focus on Early-Stage Venture Investments and $125 Million Mayfield Select Targets Later-Stage Venture Investments

(OMCL) at Deutsche Bank 41st Annual Health Care Conference

MOUNTAIN VIEW, Calif., April 29, 2016  — Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication and supply management solutions and analytics software for health care facilities, today announced they will present at the Deutsche Bank 41^st annual Health Care Conference at the InterContinental Boston Hotel, Boston, MA.

Omnicell Speakers: Randall A. Lipps, founder, chairman, president & CEO and Peter Kuipers, executive vice president & CFO

Date: Thursday, May 5, 2016
Time: 12:50 p.m. ET
Location: InterContinental Boston Hotel, Boston, MA
Availability: The audio-webcast of the live presentation may be accessed by visiting:
http://ir.omnicell.com/events.cfm

Following the conference, a replay of the audio-webcast will be archived for 90 days on the Omnicell website.

About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating innovative solutions to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for medication and supply management across the entire health care continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient’s home.

Over 4,000 customers worldwide use Omnicell automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety. The recent acquisition of Aesynt adds distinct capabilities, particularly in central pharmacy and IV robotics, creating the broadest medication management product portfolio in the industry.

The Omnicell SureMed solution provides innovative medication adherence packaging to help reduce costly hospital readmissions. In addition, these solutions enable approximately 7,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.

For more information about Omnicell, Inc. please visit www.omnicell.com.

(TIVO) Rovi to Acquire TiVo, Creating $3 Billion Entertainment Technology Leader

Rovi Corporation (NASDAQ: ROVI) and TiVo Inc. (NASDAQ: TIVO) today announced that Rovi will acquire TiVo for $10.70 per share in cash and stock for total consideration of approximately $1.1 billion. The new company combines two media and entertainment technology innovators with complementary products, services, and intellectual property assets and a common mission to write the next chapter of the consumer entertainment experience. The company will continue to be led by Tom Carson and upon closing of the transaction will adopt the iconic TiVo brand as the new company name.

“Rovi’s acquisition of TiVo, with its innovative products, talented team, and substantial intellectual property portfolio, strengthens Rovi’s position as a global leader in media discovery, metadata, analytics, and IP licensing,” said Tom Carson, CEO of Rovi. “It’s an exciting time as the media and entertainment landscape undergoes a significant evolution. The combined capabilities of TiVo and Rovi place us in a tremendous position to extend services across platforms and to a customer base that includes traditional, over-the-top and emerging players across the globe. By working together, Rovi and TiVo will revolutionize how consumers experience media and entertainment and at the same time build value for our stockholders.”

“We’re proud of TiVo’s strong innovation history and of the ongoing efforts of our team to provide best-in-class products for our loyal consumer and service provider customers,” said Naveen Chopra, Interim CEO and CFO of TiVo. “This transaction is the culmination of those efforts and the logical next step for TiVo. In joining forces with Rovi, our customers, employees and stockholders will benefit from being part of a more diversified industry leader with significantly greater market opportunities. Our combination creates a more influential global player with a commitment to product innovation, which will be incredibly well positioned to redefine television.”

Natural Synergy, Strong Business

This transaction brings together the technology and products required to achieve the company’s strategic goals and deliver substantial stockholder value.

• TiVo’s leadership in user experience and content discovery brings together traditional television, OTT and on-demand content into one experience across devices
• Rovi’s strength in guides, personalization, advertising, analytics and cloud services
• On a pro forma basis, for the twelve months ended December 31, 2016, the combined company is estimated to have more than $800 million in revenue after purchase accounting adjustments
• The combined company is expected to realize at least $100 million in annual cost synergies, with 65 percent of these synergies recognized in the first 12 months
• The expected synergies are in addition to TiVo’s targeted current year $32 million Adjusted EBITDA increase from restructuring and margin improvements
• The transaction is expected to be accretive to Rovi’s Non-GAAP EPS within the first 12 months post-close

Shared Customers, Global Reach

Rovi and TiVo serve many of the largest pay-TV operators both in the U.S. and around the world.

• Combined benefits include enhanced global reach, serving nearly 500 service providers across countries, adding more than 10 million TiVo-served households to Rovi’s current base of approximately 18 million households using Rovi guides worldwide
• Solutions will be integrated to deliver enhanced customer value and to strengthen relationships with top partners

Unique Company, Further Innovation

• The transaction will create a company with a large presence in the consumer, consumer electronic, service provider and web-scale marketplaces
• TiVo has played an iconic role in ushering in over a decade of rapid change in how consumers find, select, and watch television. These consumer innovations have also been successfully deployed for the benefit of service providers around the world
• Rovi and TiVo have invested over $1.5 billion in R&D over the past 10 years. Few companies have had a greater impact on the evolution of TV and video.
• This powerful combination of consumer innovation and service provider distribution will continue to be a unique asset of the combined company and will be further enhanced by Rovi’s prowess in areas like metadata, conversational search, and data analytics

Strong Intellectual Property Portfolios and Licensing Business

Together, Rovi and TiVo have worldwide portfolios of over 6,000 issued patents and pending applications worldwide.

• Both Rovi and TiVo have been successful in monetizing their innovations and intellectual property, with more than $3 billion in combined IP licensing revenues and past damage awards
• TiVo’s IP assets, combined with Rovi’s recent OTT partnership with Intellectual Ventures, further strengthens the company’s collective position as a leading provider of intellectual property in media and entertainment discovery

The Most Powerful Analytics in the Industry

The combined company will offer the industry’s most powerful analytics platform dedicated to media and entertainment, helping service providers and media companies strengthen consumers’ connections to the content they love.

• Industry leading monetization products for services providers, advertisers and media companies, with access to data from multiple platforms including television, mobile and cloud services
• TiVo’s unique cross-device viewership data merged with Rovi’s analytics tools will enable better targeting of media spend, improved advertising inventory yield and the creation of targeted advertising capabilities for service providers, advertisers and media companies
• TiVo’s cross-device viewership data will enhance Rovi’s Operator Insights and Subscriber Analytics tools to give service providers more visibility and more precise methods to improve customer retention and manage churn

***

Transaction Terms

• Rovi will acquire TiVo for $10.70 per share in cash and stock, approximately $1.1 billion in aggregate consideration
• Rovi will pay $2.75 per share in cash, or approximately $277 million, subject to adjustment as described under the collar mechanism below
• The remainder, $7.95 per share, will be paid in shares of common stock of a new holding company that will own both Rovi and TiVo
• Number of shares to be issued to TiVo stockholders will be calculated based on Rovi’s average VWAP over the 15 trading days ending on the third trading day prior to close (the Average Rovi Stock Price) and subject to the collar mechanism described below
• Rovi stockholders will own one share of the new holding company for each share of Rovi common stock owned as of the closing
• Offer represents a premium of approximately 40 percent over TiVo’s closing price of $7.66 on March 23, 2016, the last trading day prior to media speculation about a possible transaction
• Stock component of the consideration is expected to be a tax-free exchange to TiVo stockholders
• Cash consideration will be financed from cash on hand in the combined company, and the combined company is expected to have $150 – $270 million on hand at closing

The Board of Directors of the combined company will include participation from TiVo’s current Board.

Collar Mechanism

The stock consideration is subject to a two-way collar between Average Rovi Stock Prices of $16.00 and $25.00.

If Rovi’s stock price increases between the agreement date and the closing, TiVo stockholders will receive fewer shares (a lower exchange ratio) until the Average Rovi Stock Price reaches $25.00, at which point the exchange ratio will be fixed at 0.3180 per share.

Conversely, if Rovi’s share price decreases between signing and closing, TiVo stockholders will receive more shares (a higher exchange ratio) until the Average Rovi Stock Price reaches $18.71. Between an Average Rovi Stock Price of $18.71 (exchange ratio of 0.4250 per share) and $16.00 (exchange ratio of 0.4969 per share), Rovi has the option to pay additional cash instead of issuing more shares. If the Average Rovi Stock Price is below $16.00, Rovi may set the exchange ratio, in its sole discretion, between 0.4250 and 0.4969. If Rovi makes this election, the per share cash amount will be $10.70 minus the product of the Average Rovi Stock Price and the applicable exchange ratio that Rovi elects. In no event will the cash amount be more than $3.90 per share.

Post-transaction, current Rovi stockholders will own between 66.8 percent and 72.9 percent of the pro forma shares outstanding in the new holding company, assuming that at Average Rovi Stock Prices between $16.00 and $18.71 Rovi elects to provide more cash consideration rather than incremental shares.

Approvals Required

The boards of both companies have approved the transaction. The transaction is subject to customary closing conditions, including approval by TiVo’s and Rovi’s stockholders at special meetings to be held in connection with the transaction as well as clearance under the Hart-Scott-Rodino Antitrust Improvements Act. The companies believe that they will be able to obtain the requisite clearances on a timely basis and the transaction is expected to close in Q3 of 2016.

NOL Rights Plan

Concurrent with the approval of this transaction, Rovi’s Board approved the adoption of a Stockholder Rights Plan (the NOL Rights Plan,) designed to protect Rovi’s $1.2 billion federal Net Operating Losses (NOLs) from the effect of Section 382 under the US Internal Revenue Code, which can limit the use of the NOLs. The completion of the TiVo deal would move Rovi significantly closer to the 50 percent ownership change outlined in Section 382 and increase the likelihood of a loss of Rovi’s valuable NOLs. Rovi believes that its tax attributes represent an important corporate asset that can provide long-term stockholder benefits and should be protected. The NOL Rights Plan is similar to those adopted by numerous other public companies with significant tax assets. The NOL Rights Plan is set to expire at the earlier of completion or termination of the TiVo transaction. It is proposed that the certificate of incorporation of the new holding company will include a provision that would prohibit transfers of the holding company’s common stock that would adversely affect the holding company’s NOL tax asset following the closing. The stockholders of Rovi will be provided the opportunity to vote on the new holding company charter in connection with the approval of the transaction. Following the closing, the holding company board will, from time to time, review whether the continued effectiveness of the charter provision and any NOL Rights Plan that may be adopted continues to be in the best interests of the combined company and its stockholders.

Advisors

Evercore is serving as financial advisor to Rovi and Cooley LLP is serving as legal counsel. LionTree Advisors is serving as financial advisor to TiVo and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel.

Conference Call and Webcast Information

Rovi will host a conference call on Friday, April 29, 2016, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the transaction and Q1 financial results. A representative of TiVo will also join the call. Investors and analysts interested in participating in the conference are welcome to call 1-866-621-1214 (or international +1-706-643-4013) and reference conference ID 3449304. The conference call can also be accessed via live webcast in the Investor Relations section of Rovi’s website at http://www.rovicorp.com/.

A replay of the audio webcast will be available on Rovi Corporation’s website shortly after the live call ends and will remain on Rovi Corporation’s website until its next quarterly earnings call. Additionally, a telephonic replay of the conference call will be available through May 6, 2016 and can be accessed by calling 1-800-585-8367 (or international +1-404-537-3406) and entering conference ID 3449304.

No Offer or Solicitation

The information in this communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Non-GAAP Information

Non-GAAP EPS is defined as diluted earnings per share from continuing operations, adding back non-cash items such as equity-based compensation, amortization of intangibles, amortization or write-off of note issuance costs, non-cash interest expense recorded on convertible debt under Accounting Standards Codification (“ASC”) 470-20 (formerly known as FSP APB 14-1), mark-to-market fair value adjustments for interest rate swaps; as well as items which impact comparability that are required to be recorded under GAAP, but that the Company believes are not indicative of its core operating results such as changes in the fair value of contingent consideration, gains from the release of Sonic payroll tax withholding liabilities related to a stock option review, transaction, transition and integration costs, contested proxy election costs, restructuring and asset impairment (benefit) charges, payments to note holders and for expenses in connection with the early redemption or modification of debt, gains on sale of strategic investments and discrete income and franchise tax items, including changes in reserves.

TiVo’s “EBITDA” means income before interest income and expense, provision for income taxes and depreciation and amortization. TiVo’s “Adjusted EBITDA” is EBITDA adjusted for acquisition related charges for retention earn-outs payable to former shareholders of the business we acquired and changes in fair value of acquired business’ performance related earn-outs, transition and restructuring charges, pre-tax, stock-based compensation, litigation expenses associated with litigation matters (whether or not initiated by us) which have the potential to result in revenue generation and litigation proceeds attributable to past damage awards, but includes litigation proceeds recognized as technology licensing revenue.

Forward-Looking Statements

This press release contains “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the proposed acquisition of TiVo, the integration of TiVo’s IP assets into Rovi’s products and solutions offerings, Rovi’s plans for such offerings and customer demand for such offerings, enhanced global reach, anticipated combined company revenue, synergies and financial results, future product offerings and expected transaction timing. A number of factors could cause Rovi’s and TiVo’s actual results to differ from anticipated results expressed in such forward-looking statements. Such factors include, among others, 1) uncertainties as to the timing of the consummation of the transaction and the ability of each party to consummate the transaction; 2) uncertainty as to the actual premium that will be realized by TiVo stockholders in connection with the proposed transaction; 3) failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the transaction or integrating the businesses of Rovi and TiVo; 4) uncertainty as to the long-term value of the combined companies’ common stock; 5) unpredictability and severity of natural disasters; 6) adequacy of Rovi’s or TiVo’s risk management and loss limitation methods; 7) the resolution of intellectual property claims; 8) seasonal trends that impact consumer electronics sales; 9) the combined companies’ ability to implement their business strategy; 10) adequacy of Rovi’s, TiVo’s or the combined companies’ loss reserves; 11) retention of key executives by Rovi and TiVo; 12) intense competition from a number of sources; 13) potential loss of business from one or more major licensees; 14) general economic and market conditions; 15) the integration of businesses the combined companies may acquire or new business ventures the combined companies may start; 16) evolving legal, regulatory and tax regimes; 17) the expected amount and timing of cost savings and operating synergies; 18) failure to receive the approval of the stockholders of either Rovi or TiVo; 19) litigation related to the transaction; 20) unexpected costs, charges or expenses resulting from the transaction; and 21) other developments in the DVR and advanced television solutions market, as well as management’s response to any of the aforementioned factors. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and elsewhere, including the Risk Factors included in Rovi’s Annual Report on Form 10-K for the period ended December 31, 2015 and Rovi’s Quarterly Report on Form 10-Q for the period ended March 31, 2016, TiVo’s Annual Report on Form 10-K for the period ended January 31, 2016, and other securities filings which are on file with the Securities and Exchange Commission (available at www.sec.gov). Neither company assumes any obligation to update any forward-looking statements except as required by law.

ADDITIONAL INFORMATION ABOUT THE PROPOSED TRANSACTION AND WHERE TO FIND IT

This communication is not a solicitation of a proxy from any stockholder of Rovi, Titan Technologies Corporation or TiVo. In connection with the Agreement and Plan of Merger among Rovi, TiVo, Titan Technologies Corporation (“Parent”), Nova Acquisition Sub, Inc. and Titan Acquisition Sub, Inc., Rovi, TiVo and Parent intend to file relevant materials with the SEC, including a Registration Statement on Form S-4 filed by Parent that will contain a joint proxy statement/prospectus. ROVI AND TIVO STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION ABOUT ROVI, TIVO, PARENT AND THE PROPOSED TRANSACTION. Stockholders may obtain a free copy of the joint proxy statement/prospectus (when it becomes available), as well as any other documents filed by Rovi, Parent and TiVo with the Securities and Exchange Commission, at the Securities and Exchange Commission’s Web site at http://www.sec.gov. Stockholders may also obtain a free copy of the joint proxy statement/prospectus and the filings with the SEC that will be incorporated by reference in the joint proxy statement/prospectus from Rovi by directing a request to Rovi Investor Relations at +1-818-565-5200 and from TiVo by directing a request to MacKenzie Partners, Inc., 105 Madison Avenue, New York, New York, 10016, (212) 929-5500, proxy@mackenziepartners.com.

PARTICIPANTS IN THE SOLICITATION

Rovi, Parent, TiVo and their respective directors and executive officers and other members of their management and employees may be deemed, under Securities and Exchange Commission rules, to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding Rovi’s directors and officers can be found in its proxy statement filed with the Securities and Exchange Commission on March 10, 2016 and information regarding TiVo’s directors and officers can be found in its proxy statement filed with the Securities and Exchange Commission on June 1, 2015. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests in the transaction, by security holdings or otherwise, will be contained in the Form S-4 and the joint proxy statement/prospectus that Parent will file with the Securities and Exchange Commission when it becomes available. Stockholders may obtain a free copy of these documents as described in the preceding paragraph.

©Rovi 2016. Rovi is a registered trademark of Rovi Corporation. TiVo is a registered trademark of TiVo Inc. and/or its subsidiaries. All other brands and product names and trademarks are the registered property of their respective companies.

About TiVo

TiVo Inc. (NASDAQ: TIVO) is a global leader in next-generation television services. With global headquarters in San Jose, CA and offices in New York, NY, Durham, NC, and Warsaw, Poland, TiVo’s innovative cloud-based Software-as-a-Service solutions enable viewers to consume content across multiple screens in and out-of-the home. The TiVo solution provides an all-in-one approach for navigating the ‘content chaos’ by seamlessly combining live, recorded, on-demand and over-the-top television into one intuitive user interface with simple universal search, discovery, viewing and recording from a variety of devices, creating the ultimate viewing experience. TiVo products and services are available at retail or through a growing number of pay-TV operators worldwide. TiVo’s multiple subsidiary companies provide the broader television industry and consumer electronics manufacturers with set-top box, cloud-based video discovery and recommendation options, interactive advertising solutions, and audience research and measurement services. More information at: www.TiVo.com.

About Rovi

Rovi Corporation (NASDAQ: ROVI) is creating personalized and data-driven ways for viewers to discover the right entertainment and for providers to discover the right audiences. Chosen by top brands in entertainment content, services and devices, Rovi touches the lives of hundreds of millions of consumers by providing comprehensive solutions, customizable products and technology licensing to make discovery simple, seamless and personal. With more than 5,000 issued or pending patents worldwide, Rovi is advancing entertainment and audience discovery. Learn more at www.rovicorp.com or follow us on Twitter @rovicorp.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160429005369/en/

(WPCS) Appoints Sebastian Giordano as Its Chief Executive Officer

Company Expects Solid Growth in 2017

SUISUN, CA–(Apr 29, 2016) – WPCS International Incorporated (NASDAQ: WPCS), which specializes in low voltage communications and security contracting services, today announced that it has appointed Sebastian Giordano, 58, as Chief Executive Officer of the Company, removing the “Interim” label from his title.

Speaking on behalf of the Board of Directors, Mr. Charles Benton stated, “Since assuming the Interim CEO role in August 2013, Sebastian has demonstrated outstanding leadership skills in crafting and executing a thorough and successful restructuring of WPCS under very challenging circumstances. He now has the Company positioned to implement an exciting growth strategy that the Board fully supports. With the new fiscal year starting on May 1st, the Board believes this was the right time to take such action.”

Giordano added, “While I continue to be humbled and honored by the Board’s ongoing support, righting the ship was a total team effort; a team that fully expects to deliver strong results in fiscal 2017 and beyond.”
.
ABOUT WPCS INTERNATIONAL INCORPORATED

WPCS provides low voltage communication and security contracting services to the public services, healthcare, energy and corporate enterprise markets in the United States. For more information, please visit www.wpcs.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements with respect to the Company’s future growth opportunities and strategic plan. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

INVESTOR CONTACT

WPCS International Incorporated
Mr. David Allen
Chief Financial Officer
Phone: 707.759.6008
Email: Email Contact

(AMZN) to Open New Pickup Location Near University of Connecticut

(NASDAQ: AMZN)–Amazon today announced a new fully staffed pickup location near the University of Connecticut campus. The Amazon pickup location, the first in Connecticut, offers the UConn community a convenient location to pick up and return Amazon orders, including virtually everything one needs for life on campus, from everyday essentials to technology.

Opening in Summer 2016, this nearly 4,000-square-foot space will be located at 40 Wilbur Cross Way in Storrs Center, centrally located near the university and easily accessible to students and the greater Storrs community. Additionally, Amazon Student and Prime members will receive Free One-Day Pickup on millions of items. To learn more about Amazon Student, visit amazon.com/joinstudent.

“We are excited to bring an Amazon pickup location to the UConn and greater Storrs community,” said Ripley MacDonald, Director of Amazon Student Programs. “Whether students are ordering college essentials, electronics or snacks, Amazon will provide a convenient and secure spot for them to pick up their stuff at hours that work with their schedules.”

Since 2015, Amazon has opened staffed pickup locations at the following universities: Purdue University, University of Massachusetts Amherst, and University of California, Berkeley, as well as in the college communities of University of California, Santa Barbara, and University of Cincinnati. Amazon will also open more locations in 2016, including: University of Pennsylvania, University of California, Davis, The University of Texas at Austin, The Georgia Institute of Technology and California State University, Long Beach, as well as in the college community of University of Akron.

About Amazon Student

Amazon Student gives college students Free Two-Day Shipping on millions of items, and special offers and promotions created just for students as part of the six-month free trial. After that it’s just $49 a year—half the price of a regular Amazon Prime membership—and includes unlimited streaming of movies and TV shows with Prime Video, over a million songs with Prime Music, and access to the Kindle Owners’ Lending Library. To learn more, visit amazon.com/joinstudent.

About Amazon

Amazon.com opened on the World Wide Web in July 1995. The company is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit www.amazon.com/about.

(DWA) To Be Acquired By (CMCSA)

NBCUniversal, a division of Comcast Corporation (NASDAQ: CMCSA), today announced the acquisition of DreamWorks Animation (NASDAQ: DWA). One of the world’s most admired family brands, DreamWorks Animation creates animated feature films, television series and specials, live entertainment and related consumer products. The studio will become part of the Universal Filmed Entertainment Group, which includes Universal Pictures, Fandango, and NBCUniversal Brand Development.

“DreamWorks Animation is a great addition to NBCUniversal,” said Steve Burke, CEO of NBCUniversal. “Jeffrey Katzenberg and the DreamWorks organization have created a dynamic film brand and a deep library of intellectual property. DreamWorks will help us grow our film, television, theme parks and consumer products businesses for years to come. We have enjoyed extraordinary success over the last six years in animation with the emergence of Illumination Entertainment and its brilliant team at Illumination Mac Guff studio. The prospects for our future together are tremendous. We are fortunate to have Illumination founder Chris Meledandri to help guide the growth of the DreamWorks Animation business in the future.”

Under the terms of the agreement, DreamWorks Animation has an equity value of approximately $3.8 billion. DreamWorks Animation stockholders will receive $41 in cash for each share of DreamWorks Animation common stock. The agreement has been approved by the boards of directors of DreamWorks Animation and Comcast, and the controlling shareholder of DreamWorks Animation has approved the agreement by written consent.

The transaction is expected to close by the end of 2016, subject to receipt of antitrust approvals in the U.S. and abroad, as well as the satisfaction of other customary closing conditions.

Following the completion of the transaction, DreamWorks Animation CEO and co-founder Jeffrey Katzenberg will become Chairman of DreamWorks New Media, which will be comprised of the company’s ownership interests in Awesomeness TV and NOVA. Katzenberg will also serve as a consultant to NBCUniversal.

“Having spent the past two decades working together with our team to build DreamWorks Animation into one of the world’s most beloved brands, I am proud to say that NBCUniversal is the perfect home for our company; a home that will embrace the legacy of our storytelling and grow our businesses to their fullest potential,” said Katzenberg. “This agreement not only delivers significant value for our shareholders, but also supports NBCUniversal’s growing family entertainment business. As for my role, I am incredibly excited to continue exploring the potential of AwesomenessTV, NOVA and other new media opportunities, and can’t wait to get started.”

The acquisition gives NBCUniversal broader reach to a host of new audiences in the highly competitive kids and family entertainment space, in both TV and film. It includes popular DreamWorks Animation film franchise properties, such as Shrek, Madagascar, Kung Fu Panda and How to Train Your Dragon. It also includes a thriving TV operation that is a significant supplier of family programming, with hundreds of hours of original, animated content distributed across linear and SVOD platforms in more than 130 countries. Additionally, DreamWorks Classics, a large library of classic characters, including Where’s Waldo, and Rudolph the Red-Nosed Reindeer, will become part of the NBCUniversal portfolio, along with a successful consumer products business.

Comcast was advised by Davis Polk & Wardwell LLP on legal matters. DreamWorks Animation was advised on financial matters by Centerview Partners and on legal matters by Cravath, Swaine & Moore LLP. DreamWorks Animation’s Board of Directors was advised on legal matters by Munger Tolles & Olson LLP.

About NBCUniversal

NBCUniversal is one of the world’s leading media and entertainment companies in the development, production, and marketing of entertainment, news and information to a global audience. NBCUniversal owns and operates a valuable portfolio of news and entertainment television networks, a premier motion picture company, significant television production operations, a leading television stations group, world-renowned theme parks, and a suite of leading Internet-based businesses. NBCUniversal is a division of Comcast Corporation.

About DreamWorks Animation

DreamWorks Animation (Nasdaq: DWA) is a global family entertainment company with business interests that span feature film and television production; licensing and consumer products; location-based entertainment; and new media properties, including the Company’s controlling interest in AwesomenessTV. The Company’s feature film heritage includes many of the world’s most-beloved characters and franchises, including Shrek, Madagascar, Kung Fu Panda and How to Train Your Dragon, while its 32 feature film releases have amassed more than $13 billion in global box office receipts. DWA’s television business has quickly become one of the world’s leading suppliers of high-quality family programming, reaching consumers on linear and on-demand platforms in more than 130 countries and winning a total of 25 Emmy™ Awards to date. The Company’s deep portfolio of intellectual property is supported by a robust, worldwide consumer products practice, which includes licensing, and location-based entertainment venues around the world. The Company is also the majority owner of AwesomenessTV, a leading video destination for Generation Z and Millennial audiences, and also owns 45% of Oriental DreamWorks, a world-class animation studio in China that produces family entertainment for both Chinese and global audiences.

NOTE: This press release contains forward-looking statements. Readers are cautioned that such forward-looking statements involve risks and uncertainties that could cause actual events or our actual results to differ materially from those expressed in any such forward-looking statements. Such forward-looking statements include the possible benefits of the proposed DreamWorks Animation acquisition to the NBCUniversal business. Readers are directed to Comcast’s and DreamWorks Animation’s periodic and other reports filed with the Securities and Exchange Commission (SEC) for a description of such risks and uncertainties. Neither Comcast nor DreamWorks Animation undertakes any obligation to update any forward-looking statements.

(NHLD) & (FBIO) Announce Share Tender Offer Agreement

Subsidiary of Fortress Biotech to Make $3.25/Share Tender Offer for All Outstanding National Holdings Shares If Less Than 80% of Outstanding Shares Are Tendered, National Holdings Will Remain Publicly-Traded Shareholders Post-Tender Offer to Receive From National a 5-Year Warrant With an Exercise Price of $3.25 if National Holdings Remains Publicly-Traded, Subject to Certain Conditions Fortress Biotech to Implement a New Business Plan That Cuts Costs and Enhances the Platform of Offerings for the 800+ Independent Advisors and Their Clients Investment Banking Operations Will Initially Focus on Building a World-class Biotech/Life Sciences Franchise With Additional Key Verticals to Follow

(DHRM) Receives US$20 Million Strategic Investment from Liaison Interactive

BEIJING, April 28, 2016  — Dehaier Medical Systems Ltd. (Nasdaq: DHRM) (“Dehaier Medical” or the “Company”), which develops, markets and sells medical devices and wearable sleep respiratory products in China and international markets, today announced that it entered into a definitive securities purchase agreement (the “Agreement”) with Hangzhou Liaison Interactive Information Technology Co. Ltd. (“Liaison Interactive” or the “Purchaser”), a publicly listed company on the Shenzhen Stock Exchange (Trading Ticker: 002280) pursuant to which the Liaison Interactive has agreed to purchase 11,111,111 restricted common shares of the Company (the “Shares”) for an aggregate of US$20,000,000 (the “Purchase Price”). The Purchase Price is US$1.80 per share, which represents a 35% premium to Dehaier Medical’s closing price of $1.33 on April 27, 2016.

In consideration of the payment by the Buyer of the Purchase Price, the Buyer and its designees will also receive warrants to purchase 1,000,000 restricted common shares of the Company at a purchase price of US$2.20 per share (the “Warrants”).  The Warrants are exercisable by the Buyer or its designees in whole or in part and are exercisable at any time after the Closing.

The Shares issued to the Purchaser have not been and are not being registered under the 1933 Act, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder or (B) the Buyer shall have delivered to the Company an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Shares to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration. Closing under the Agreement is subject to compliance with customary closing conditions and is anticipated to occur on or before June 30, 2016.

“The Liaison Interactive investment dramatically improves our ability to expand our wearable medical device business and to launch other new smart wearable devices and mobile medical solutions over the next few years,” said Mr. Ping Chen, Chief Executive Officer of Dehaier Medical. “The investment also helps optimize our overall strategies, increase our market penetration and strengthen our competitiveness in the medical wearable device segment.

“Liaison Interactive is committed to providing mobile internet products and services for its customers, including operation systems and software solutions platform, game publishing, distribution and smart wearable devices, which are currently a major focus of its business. Liaison Interactive entered the virtual reality (‘VR’) smart terminal market in 2015, acquiring ‘Avegant Glyph’ brand of hardware and software products. ‘Avegant Glyph’ is a retina glasses using VR technology, providing users ultimate visual experiences. We believe that by investing in the Company, Liaison Interactive can open up and further expand its strategic presence in the smart hardware space within the medical field.

“Dehaier Medical, focusing on smart wearable medical devices and services for OSAS patients, has cooperated with hundreds of medical institutions in China and is attempting to expand into the individual customer-oriented smart hardware market. By leveraging Liaison Interactive’s extensive customer base in the Chinese mobile internet market, Dehaier anticipates growing its market share in China. It is the exact type of collaboration that we would anticipate from a strategic investor like Liaison Interactive, and we believe it will lead to a new revenue stream for us in the future.”

About Hangzhou Liaison Interactive Information Technology Co. Ltd.

Liaison Interactive, formerly known as Beijing Digital Grid Technology Co., Ltd. was founded in 2007 as a leading mobile Internet product and services provider in the industry. On October 24, 2014, China Securities Regulatory Commission approved the asset restructuring application of Beijing Digital Grid Technology Co., ltd. and the listed company Hangzhou New Century Information Technology Co., Ltd. After the restructuring, listed entity Liaison Interactive (002280) became China’s first listed mobile Internet company. Liaison Interactive has three core business units. Digital Grid Department focuses on innovations in products and technologies. Interactive Entertainment Department focuses on mobile game developing and operating. Intelligent Hardware Department focuses on one of most important business strategies striving to be a world-class developer. Based in Beijing, Liaison Interactive has set up subsidiaries and branches in Shanghai, Guangzhou, Hong Kong, Shenzhen, Hangzhou, Nanjing, Shenyang and the U.S. For more information, please visit http://www.lianluo.com.

About Dehaier Medical Systems Ltd.

Dehaier Medical develops, markets and sells medical products, including medical devices and wearable sleep respiratory products in China and international markets. The company develops and assembles its self-branded medical devices and sleep respiratory products from third-party components. Dehaier is committed to becoming the solution provider of medical smart wearable devices and professional services. Dehaier is transforming from a traditional medical equipment supplier to a high-tech enterprise in the field of mobile medical and smart wearable devices. The main business of Dehaier is providing overall solutions including accurate screening, efficient treatment and treatment evaluation for obstructive sleep apnea syndrome (“OSAS”) patients. With the cutting-edge photoplethysomography analysis technology and state-of-the-art sleep diagnosis device, Dehaier made the first application of cloud technology in sleep medicine by managing to upload patients’ records, patient information management, and analysis to the cloud. Dehaier Medical provides sleep diagnostic products and services for inpatients and outpatients in Chinese medical institutions including chronic diseases therapy departments in public hospitals, patients in private physical examination centers and VIP customers of life insurance companies. Dehaier Medical’s technology is based on six patents and eleven software copyrights. More information may be found at http://www.dehaier.com.cn.

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, fulfillment of bids and contracts, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

Dehaier Medical Systems Limited
Janice Wang
+86 10-5166-0080 ext. 211
investors@dehaier.com.cn

(PRGN) Recent Developments on its Debt Agreements, Newbuilding Contracts

ATHENS, Greece, April 28, 2016  — Paragon Shipping Inc. (“Paragon” or the “Company”) today announced the following updates on its debt agreements, newbuilding contracts and other corporate actions:

Newbuilding Contracts

The Company has entered into an agreement with Jiangsu Yangzijiang Shipbuilding Co., or Yangzijiang, to extend the deliveries of its three Kamsarmax newbuilding drybulk carriers (Hull numbers YZJ1144, YZJ1145 and YZJ1142), to September 30, 2016, October 31, 2016 and November 30, 2016, respectively, subject to certain conditions.

Bank of Ireland – Unsecured Paid-in-Kind Note (“PIK Note”)

In January 2016, the Company agreed with Bank of Ireland to apply the total net proceeds from the sale of M/V Kind Seas towards an immediate prepayment of the loan facility. An amount of $2.2 million was written-off and the remaining amount of $2.2 million, plus accrued interest, was converted into a PIK Note. The PIK Note was non-amortizing and had a maturity date of December 31, 2020, at which time it would be repaid at par. Interest on the PIK Note would accrue on a quarterly basis at an interest rate equal to the aggregate of 2.5% and the applicable LIBOR, and would be treated as payment-in-kind. On April 11, 2016, the Company received a notice of cancellation, pursuant to which it was discharged from all of its obligations under the PIK Note.

Other Corporate Actions

On April 26, 2016, the Company and Mr. Michael Bodouroglou, the Company’s Chairman, President, Chief Executive Officer and Interim Chief Financial Officer, filed a law suit against Tradewinds and their financial reporter, Mr. Joe Brady Stamford for defamation damages. In particular on February 18, 2016, Tradewinds reported that the Company had obtained its Board of Directors approval for filing bankruptcy under Chapter 11. The Company and its Board of Directors declared that the above statement was totally untrue. The Company believes that such false statements had a negative impact on the Company, its reputation and stock price. The lawsuit was submitted before the Prosecutor of the Criminal Court of Athens.

Senior Unsecured Notes due 2021

In relation to the issued and outstanding senior unsecured notes due 2021 that bear interest at a rate of 8.375% per year (“Unsecured Notes”), the Company will not proceed with the interest payment, which is due on May 15, 2016, due to lack of liquidity.

Forward-Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risk factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Risks, uncertainties and assumptions include the possibility that expected benefits may not materialize as expected as well as other risks that have been included in filings with the Securities and Exchange Commission, all of which are available at www.sec.gov.

About Paragon Shipping Inc.

Paragon Shipping is an international shipping company incorporated under the laws of the Republic of the Marshall Islands with executive offices in Athens, Greece, specializing in the transportation of drybulk cargoes. Paragon Shipping’s current newbuilding contracts consist of three Kamsarmax drybulk carriers. The Company’s common shares and Unsecured Notes trade on the NASDAQ Capital Market under the symbols “PRGN” and “PRGNL,” respectively.  For more information, visit: www.paragonship.com. The information contained on Paragon Shipping’s website does not constitute part of this press release.

Contacts:

Paragon Shipping Inc.
ir@paragonshipping.gr

DresnerAllenCaron
Rudy Barrio (Investors)
rbarrio@dresnerallencaron.com
(212) 691-8087

(MKGI) Recruiter.com Partners With Monaker Group to Develop Custom Travel Club

Recruiter.com Has Partnered With Innovative Travel Company Monaker Group to Develop Its Custom Travel Club

(RESN) Signs Its First Licensing Agreement with Existing Tier One Customer

Resonant Inc. (NASDAQ: RESN), a designer of filters for radio frequency, or RF, front-ends that specializes in delivering designs for difficult bands and complex requirements, today announced it signed its first licensing agreement with an existing customer. This license agreement follows the development engagement that was outlined in the memorandum of understanding signed with this customer in February 2016.

“Securing our first licensing agreement is the next major milestone resulting from years of development of our Infinite Synthesized Network®, or ISN®, tools and technology. This license agreement encompasses two high-volume Surface Acoustic Wave, or SAW, duplexer designs for filters traditionally fabricated as Bulk Acoustic Wave, or BAW duplexers. As we advance this project to meet the customer’s aggressive schedule, we look forward to further validating our ability to achieve complex and competitive RF front-end filters that we believe can be developed in less than half the time and manufactured at approximately half the unit cost of traditional designs,” said Terry Lingren, CEO and Co-Founder of Resonant Inc.

“Our continued expansion of design capabilities for these difficult bands has enabled us to develop low cost non-temperature compensated SAW duplexers that we believe will deliver comparable performance to the more expensive BAW and FBAR duplexers. We also believe these design tools can address the increasing complexity required by carrier aggregation. This trend, along with the industry-wide constraint on design capacity, are significant drivers of our growing opportunities,” concluded Lingren.

Design acceptance payments and royalty terms have been agreed upon, but will not be disclosed due to the confidential nature of such agreements. The customer, or licensee, is targeting new OEM handsets for these filters. While not guaranteed, there is a potential that one if not both of these products could start to produce revenues before the end of 2016.

About Resonant® Inc.

Resonant is creating innovative filter designs for the RF front-end, or RFFE, for the mobile device industry. The RFFE is the circuitry in a mobile device responsible for the radio frequency signal processing and is located between the device’s antenna and its digital baseband. Filters are a critical component of the RFFE that selects the desired radio frequency signals and rejects unwanted signals and noise.

About Resonant’s ISN® Technology

Resonant can create designs for hard bands and complex requirements that can be manufactured for half the cost and developed in half the time of traditional approaches. The Company’s large suite of proprietary mathematical methods, software design tools and network synthesis techniques enable it to explore a much bigger set of possible solutions and quickly derive the better ones. These improved filters still use existing manufacturing methods (i.e. SAW) and can perform as well as those using higher cost methods (i.e. BAW). While most of the industry designs surface acoustic wave filters using a coupling-of-modes model, Resonant uses circuit models and physical models. Circuit models are computationally much faster, and physical models are highly accurate models based entirely on fundamental material properties and dimensions. Resonant’s method delivers excellent predictability, enabling achievement of the desired product performance in roughly half as many turns through the fab. In addition, because Resonant’s models are fundamental, integration with its foundry and fab customers is eased because its models speak the “fab language” of basic material properties and dimensions.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements, which include the following subjects, among others: the status of filter designs under development, the capabilities of our filter designs, and, the timing and amount of future royalty streams. Forward-looking statements are made as of the date of this document and are inherently subject to risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, the following: our limited operating history; our ability to complete designs that meet customer specifications; the ability of our customers (or their manufacturers) to fabricate our designs in commercial quantities; the ability of our designs to significantly lower costs compared to other designs and solutions; the risk that the intense competition and rapid technological change in our industry renders our designs less useful or obsolete; our ability to find, recruit and retain the highly skilled personnel required for our design process in sufficient numbers to support our growth; our ability to manage growth; and general market, economic and business conditions. Additional factors that could cause actual results to differ materially from those anticipated by our forward-looking statements are under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our most recent Annual Report (Form 10-K) or Quarterly Report (Form 10-Q) filed with the Securities and Exchange Commission. Forward-looking statements are made as of the date of this release, and we expressly disclaim any obligation or undertaking to update forward-looking statements.

(DRYS) Announces Availability of 2015 Annual Report on Form 20-F

(LGCY) Will They Hit or Miss; Earnings Estimates

MIDLAND, TX / April 27, 2016 / Legacy Reserves LP (NASDAQ: LGCY) is a master limited partnership headquartered in Midland, Texas, focused on the acquisition and development of oil and natural gas properties primarily located in the Permian Basin, East Texas, Rocky Mountain and Mid-Continent regions of the United States. The following report focuses on earnings estimates, analyst comments, price targets and seeks to answer the question, will Legacy hit or miss with their next earnings report.

Get multiple analyst estimates, price targets, earnings information and comments which we have compiled here. There is no cost or obligation to view the full report: http://broadstreetalerts.com/legacy-earnings-analyst-rating/.

About Broad Street Alerts

We make the connection between sophisticated investors and high quality small cap companies. An issuer of reports that provide a straightforward assessment of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Safe Harbor Statement

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management’s own knowledge and assessment of the Company’s industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements

Compliance Procedure

Content is researched, written and reviewed on a best-effort basis by a 3rd party analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and report. For more information and services provided beyond this press release please use contact information provided below.

Contact: editor@BroadStreetAlerts.com

(NVIV) Conversion of a Fourth Patient Implanted with the Neuro-Spinal Scaffold™

InVivo Therapeutics Holdings Corp. (NVIV) today announced that the sixth-implanted patient in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. This is the fourth out of the first six patients (67%) with at least two months of follow up data to have had an AIS grade improvement.

The Objective Performance Criterion (OPC), a measure of study success for the INSPIRE study, is defined as 25% or more of the patients having improved by at least one AIS grade by six months post-implantation. Several large natural history databases indicate that fewer than 16% of patients with complete thoracic injuries have an AIS grade improvement by six months post-injury. *

“We’re encouraged by the progress the patient has made in the first two months after injury. It’s still early in the patient’s recovery period, and we look forward to monitoring this patient for signs of further neurological recovery,” said Wilson (Zack) Ray, M.D. Dr. Ray performed the implantation at the Barnes-Jewish Hospital at Washington University Medical Center in St. Louis, MO.

“The proportion of patients in the INSPIRE study that have recovered some neurological function is impressive. This most recent conversion brings us closer to achieving the study’s Objective Performance Criterion of five patient conversions. We will be enrolling 13 additional evaluable patients in order to reach 20 patients at six months, and we only need to observe one additional conversion in order to meet the OPC,” said Mark Perrin, InVivo’s Chief Executive Officer and Chairman. “Our goal is to approach full enrollment by the end of this year and file for Humanitarian Device Exemption approval next year.”

All patients enrolled in the INSPIRE study have complete (AIS A) spinal cord injuries at the time of enrollment. In the time between the one-month and the two-month post-injury assessment, the sixth patient treated improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. The ASIA Impairment Scale (AIS) is a five grade scale (AIS A-E) that measures the severity of a spinal cord injury.

About The INSPIRE Study

The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury, is designed to demonstrate the safety and probable benefit of the Neuro-Spinal Scaffold™ for the treatment of complete T2-T12/L1 spinal cord injury in support of a Humanitarian Device Exemption (HDE) application for approval. For more information, refer to https://clinicaltrials.gov/ct2/show/study/NCT02138110.

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold, progress toward achievement of OPC for The INSPIRE Study, the expected timing of full enrollment in the study, and the timing of the submission of the Humanitarian Device Exemption (HDE). Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the impact of achieving the OPC on the FDA approval process; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

* Zariffa et al., Spinal Cord (2011); Lee et al., J. Spinal Cord Med. (2014); Fawcett et al., Spinal Cord (2007)

(OGXI) Analyst Review and Estimates

BOTHELL, WA and VANCOUVER, BC / April 26, 2016 / OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company’s product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell’s adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5). There are a several analyst covering OGXI’s securities. The focus of the following report is several analyst rating and the companies drug pipeline and progress.

Get the all the analyst estimates and price targets and comments that we have compiled here. There is no cost or obligation to view the full report: http://broadstreetalerts.com/analyst-review-oncogenex/.

About Broad Street Alerts

We make the connection between sophisticated investors and high quality small cap companies. An issuer of reports that provide a straightforward assessment of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Safe Harbor Statement

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management’s own knowledge and assessment of the Company’s industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements

Compliance Procedure

Content is researched, written and reviewed on a best-effort basis by a 3rd party analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and report. For more information and services provided beyond this press release please use contact information provided below.

Contact: editor@BroadStreetAlerts.com

(SMMT) IND Cleared by FDA Allowing Expansion of PhaseOut DMD

Enrolment of Patients with DMD in the US Expected to Start 3Q 2016
Utrophin Modulation Offers Differentiated Approach in DMD

OXFORD, United Kingdom, April 26, 2016 — Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces that the US Food and Drug Administration has cleared the Company’s investigational new drug (‘IND’) application to expand the Phase 2 proof of concept clinical trial called PhaseOut DMD to trial sites in the US. PhaseOut DMD will evaluate the Company’s lead utrophin modulator, ezutromid (formerly known as SMT C1100), in patients with DMD at sites in the UK and the US.

In contrast to many current therapeutic approaches to DMD, utrophin modulation has the potential to treat all boys and young men with DMD, regardless of their underlying dystrophin gene mutation.

“The IND clearance for PhaseOut DMD paves the way to expand PhaseOut DMD into the US and will provide access to a wider network of leading physicians in DMD as we seek to improve the lives of patients and families living with this devastating disease,” said Ralf Rosskamp, MD, Chief Medical Officer of Summit. “PhaseOut DMD aims to show the potential benefits of ezutromid as a disease modifying approach for DMD for the first time in patients, and this approach could ultimately benefit the entire DMD patient population.”

Summit expects to begin enrolling patients into US sites in the third quarter of 2016.

About PhaseOut DMD
PhaseOut DMD aims to provide proof of concept for ezutromid (SMT C1100) and utrophin modulation by measuring muscle fat infiltration, as well as by measuring utrophin protein and muscle fibre regeneration in muscle biopsies. The primary endpoint of the open-label trial is the change from baseline in magnetic resonance imaging parameters related to fat infiltration and inflammation of the leg muscles. Exploratory endpoints include the six-minute walk distance, the North Star Ambulatory Assessment and patient reported outcomes. PhaseOut DMD is a 48-week open-label trial expected to enrol up to 40 boys ranging in age from their fifth to their tenth birthdays at sites in the UK and the US.

About Utrophin Modulation in DMD
DMD is a progressive muscle wasting disease that affects around 50,000 boys and young men in the developed world. The disease is caused by different genetic faults in the gene that encodes dystrophin, a protein that is essential for the healthy function of all muscles. There is currently no cure for DMD and life expectancy is into the late twenties. Utrophin protein is functionally and structurally similar to dystrophin. In preclinical studies, the continued expression of utrophin has a meaningful, positive effect on muscle performance. Summit believes that utrophin modulation has the potential to slow down or even stop the progression of DMD, regardless of the underlying dystrophin gene mutation. Summit also believes that utrophin modulation could potentially be complementary to other therapeutic approaches for DMD. The Company’s lead utrophin modulator, ezutromid*, is an orally administered, small molecule. DMD is an orphan disease, and the US Food and Drug Administration and the European Medicines Agency have granted orphan drug status to ezutromid. Orphan drugs receive a number of benefits including additional regulatory support and a period of market exclusivity following approval.

*Ezutromid is the international nonproprietary name (‘INN’) recommended by the World Health Organization for SMT C1100. INNs, also known as generic names, are used globally to identify pharmaceutical substances.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Forward-looking Statements
Any statements in this press release about Summit’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of Summit’s product candidates, the therapeutic potential of Summit’s product candidates, and the timing of initiation, completion and availability of data from clinical trials, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from on-going and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for Summit’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of filings that Summit makes with the Securities and Exchange Commission including Summit’s Annual Report on Form 20-F for the fiscal year ended January 31, 2015.  Accordingly readers should not place undue reliance on forward looking statements or information. In addition, any forward looking statements included in this press release represent Summit’s views only as of the date of this release and should not be relied upon as representing Summit’s views as of any subsequent date. Summit specifically disclaims any obligation to update any forward-looking statements included in this press release.

(OGES) and CEO Barber to Commence 3 Part, 90-Minute TV Series: “Power Up America”

(CNCK) Expands Its Board of Advisors and Appoints Dennis Fredricks

Joins Dr. Marc Siegel Who Currently Sits on the Company’s Board of Advisors